GREY:ATBPF - Post by User
Comment by
MrMugsyon May 25, 2022 7:52am
255 Views
Post# 34705715
RE:Significance
RE:SignificanceDoccole wrote: Any significance to the corporate shakeup?
Yes - I think the shuffle is now needed - entering a new corporate phase.
Since Bloom Burton, Dan was really positive on all fronts. He focused on Hoffman for his background in US Capital markets. I think that's the significance going forward (and Hoffman's pain background).
The goal is to be the name-of-the-game in the operating room - and - it seems easy enough for OTENA.
On the co-chair side ... continue to have the business leadership from Macnee and the drug development leadership from Wallace.
Wallace will be focusing on our drug pipeline and that's a good indication that things are getting heated in that space. Not only are we waiting for an update on 352 but we're in the middle of pushing acute to P2 and for a solution in chronic. I'm anticipating a renewed focus on 340 at some point too. Just so much on the go (science-wise) and that's where we need John to create value.
IMO